Kingwood – Texas, Apr-16-2021
Cytorex Biosciences Inc, (Cytorex), a South Florida biotechnology company with research and development facilities in Texas, announced today that a poster with the results of a compassionate and humanitarian clinical study conducted in the city of Mérida-Venezuela, evaluating the efficacy of a topical therapeutic agent developed with its Cytoreg® therapeutic technology in patients diagnosed with diabetic foot, has been accepted for presentation at the 81st Scientific Session of the American Diabetes Association to be held June 25-29, 2021.
Cytorex Biosciences Inc.'s novel proposal for the treatment of the diabetic foot is a highly effective therapeutic solution with no side effects. It would allow the topical treatment of ulcers and infections in the extremities of patients with diabetes and could have an impact on the reduction of amputations.
Dr. Dario Carrillo, diabetic foot specialist and leader of the clinical research conducted, states: "It has been a surprising and pleasing experience to appreciate the efficacy of using this novel topical solution on the lesions. It allowed us to replace the use of antibiotics on the lesions and to obtain greater efficacy in terms of tissue response".
It is important to note that, according to the non-profit association, D-Foot International of Belgium, "Diabetic foot is one of the most common, costly and serious complications of diabetes. Amputation in people with diabetes is 10 to 20 times more common than in people without diabetes and it is estimated that every 30 seconds a lower limb or part of a lower limb is lost somewhere in the world as a result of diabetes. The diabetic foot can result in a significant economic, social and public health burden; especially in low-income communities, if there is no appropriate educational program, nor adequate and appropriate footwear.
Cytoreg® Technology is a broad and novel technological proposal from which therapeutic agents are obtained to treat different pathologies. This technology platform provides an ionic transport complex (Electrons) in high concentrations that is used in each agent to be designed for the treatment of different diseases. In the case of the topical agent used in these compassionate and humanitarian clinical trials of diabetic foot, there are no irritation or caustic effects on the skin.Los resultados de este trabajo de investigación clínica podrán apreciarse durante la realización del evento la 81ª Sesión Científica y en los medios de difusión de la ADA - Asociación Estadounidense de Diabetes.
"The Adult Population living with diabetes, according to D-Foot International between 2017 and 2045 is estimated to grow by 47% from 425 Million in 2017 to 628 Million in 2045. Diabetic foot and lower extremity complications are severe and chronic and may affect between 40 and 60 million people with diabetes worldwide. We are confident that the medical and scientific community worldwide will appreciate the results of our therapeutic contribution, which will be exposed in this important event, which is a worldwide reference in the field of Diabetes and more specifically in Diabetic Foot.".... says William Jimenez C, CEO -President of Cytorex Biosciences Inc.


About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is a small innovative biotechnology company based in South Florida with a research and development coordination center in Kingwood, Texas focused on the development and research of ionic therapeutic agents, based on the Cytoreg® therapeutic technology, for the development of therapeutic agents for the treatment of pathologies such as cancer, autoimmune diseases, neurodegenerative diseases, kidney stones, pathologies derived from bacteria, viruses such as Ebola and COVID among other pathologies. Cytorex has worldwide intellectual property rights on its technologies, as well as with other new patents pending and others in development. Cytorex is currently in the pre-clinical phase of development for a therapeutic agent for the treatment of brain tumors of the Glioblastoma Multiforme type.
For more information about Cytorex Biosciences, Inc., please visit the company's website at http://www.cytorex.com